Released Aug 8, 2018, after the close
10-Q filed Aug 8, 2018, 39 days after period end · 0001144204-18-042893
Q2 2018 · 10-Q
Revenue$3.22M$3.22M +36.4% vs Q2 2017−9.7% vs Q1 2018
Net Income-$26.81M-$26.81M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$1.30-$1.30 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$27,166,000N/M
Operating Cash Flowderived-$16,047,000N/M
Free Cash Flowderived-$16,100,000N/M
Margins · derived
Operating margin-844.2%−269.2 pt vs Q2 2017
Net margin-833.0%−256.6 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $3.22M | $2.36M | — | — |
| Net Income | -$26.81M | -$13.60M | -$10.15M | -$6.94M |
| EPS Diluted | -$1.30 | -$780.00 | -$0.59 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR